Delivery Order HHSN271201600004I-HHSN27100001
Award Date
7/8/16
Potential Completion Date
6/30/26
Potential Value
$410K
Federal Agency
National Institute on Drug Abuse
Awardee
Duke University
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27705, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-no-fee Delivery Order contract awarded by the National Institute of Allergy and Infectious Diseases, a civilian agency, to Duke University for a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The contract has a ceiling value of $416,539.69 and a period of performance through August 31, 2017. This order is part of a larger Therapeutics Against Infectious Diseases Phase 1 Indefinite Delivery Indefinite Quantity (IDIQ) contract vehicle. No set-aside...
This federal contract award is for a $109,969 Phase 1 Clinical Trial to be conducted by Duke University Office of Research Administration Division for the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases. The contract is a delivery order against the parent Therapeutics Against Infectious Diseases Phase 1 multiple-award IDIQ contract. Duke University, a private non-profit research university, is the prime...
This is a federal contract award to Duke University, a private university and non-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS). The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" indefinite delivery/indefinite quantity (IDIQ) contract vehicle, with a ceiling value of $212,814.70....
Duke University, as prime contractor, is providing clinical research and immunization safety assessment services under a cost-no-fee delivery order valued at $489,565. This award is issued against the prime IDIQ contract held by Duke University from the Centers for Disease Control and Prevention, entitled "Phase I Clinical Trials for Development of Neurotherapeutics", with a potential value of $86 million through September 2028. No set-aside designation was used for this delivery...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $138,686 delivery order to Duke University's Office of Research Administration Division for a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The contract has a potential value of $115,875.31 and a completion date of December 14, 2018. This delivery order is part of a larger Therapeutics Against Infectious Diseases Phase 1 indefinite...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $136,864.00 delivery order contract to Duke University for Phase 1 clinical trial unit services to support Therapeutics Against Infectious Diseases research. The contract is not set aside and is part of a master Indefinite Delivery Indefinite Quantity (IDIQ) contract focused on therapeutics against infectious diseases. As the prime contractor, Duke...
This is a cost-plus-fixed-fee delivery order awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Duke University for a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The potential value of the award is $126,086.19. The order was issued against the Therapeutics Against Infectious Diseases Phase 1 master contract. No set-aside designation was used. As the prime contractor, Duke University will provide clinical...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Duke University. The contract is for a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases and has a ceiling value of $127,244.88. It is a delivery order awarded under the Therapeutics Against Infectious Diseases Phase 1 contract vehicle. The contract does not have a set-aside designation. Duke University, a private non-profit educational...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $1,436,776 firm fixed price delivery order to Altasciences Clinical Kansas Inc. to conduct a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of an investigational agent from September 3, 2024 to March 2, 2026. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for pharmacokinetic and pharmacodynamic...
This federal contract award is for a Phase 1 clinical trial protocol development, implementation, and research laboratory analysis task for a therapeutic against malaria. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Duke University for $40,257. This task is part of the Therapeutics Against Infectious Diseases Phase 1 contract vehicle, which is a larger program supporting the development of therapeutics against infectious...